# Theraclone Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/theraclone-sciences

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.theraclone-sciences.com
- Total disclosed funding: $56M
- Latest round: Series C (May 6, 2015)
- Investors on record: 10

## About

Theraclone Sciences is focused on the discovery and development of human monoclonal antibodies, utilizing advanced screening technologies to provide therapeutic options for infectious diseases and cancers.Founded in 2004, Theraclone Sciences operates out of Seattle, US, specializing in human monoclonal antibody development. The firm has raised a total of USD 3.08 mn in multiple funding rounds, with the latest being a Series C in May 2015, led by ARCH Venture Partners, Canaan Partners, and HealthCare Ventures. Theraclone's founder, who has not been publicly named, has a history of involvement in biotechnology ventures. The company's operations and strategies have remained consistent since its inception, focusing on antibody discovery and licensing. As of its last funding round, the current company valuation is approximately USD 42.50 mn.Theraclone Sciences specializes in the discovery and development of human monoclonal antibodies through its advanced screening platform technology. The company's primary focus is on identifying rare antibodies that can effectively target infections and diseases, providing innovative therapeutic options. Among its notable offerings, Theraclone has licensed its HIV broadly neutralizing fully-human antibodies to Gilead, which are being developed as part of an HIV-cure regimen. Additionally, the company has partnered with OncoResponse, allowing the application of its platform technology within the oncology sector. Theraclone's products cater to pharmaceutical companies and research institutions, primarily targeting markets in North America and Europe, where there is a significant demand for therapeutic solutions in infectious diseases and cancer treatment.Theraclone Sciences generates revenue through strategic licensing agreements and partnerships with pharmaceutical companies, allowing for the commercialization of its proprietary antibody products. The firm engages in business transactions primarily through B2B relationships, where it licenses its technology and antibody candidates to larger firms in exchange for royalties and milestone payments based on developmental progress. The revenue structure is bolstered by these partnerships, with potential for ongoing revenue streams from successful product developments. While specific pricing plans for their offerings are not disclosed, the business model is geared toward maximizing the value of its intellectual property through collaborative ventures that align with the objectives of its partners in the biotechnology and pharmaceutical sectors.In May 2015, Theraclone Sciences raised USD 3.08 mn in Series C funding, which is intended to support the ongoing development of its antibody programs. The company plans to design and launch new monoclonal antibody products aimed at addressing unmet medical needs in infectious diseases and oncology. Additionally, Theraclone is exploring expansion into international markets beyond North America and Europe, with specific strategies to penetrate emerging markets in Asia by 2025. The recent funding will facilitate these initiatives, enhancing their research capabilities and enabling potential partnerships with local pharmaceutical firms.

## Funding rounds

- Series C, May 6, 2015, $3.1M — ARCH Venture Partners, HealthCare Ventures, Canaan Partners
- Series B, Mar 25, 2013, $8M — ARCH Venture Partners, HealthCare Ventures, Versant Ventures, Canaan Partners, Alexandria Venture Investments, Amgen Ventures, MPM BioImpact, Zenyaku Kogyo Co., Ltd.
- Series B, Sep 9, 2011, $11M — ARCH Venture Partners, HealthCare Ventures, Canaan Partners, Alexandria Venture Investments, Amgen Ventures, MPM BioImpact
- Series B, Mar 17, 2010, $1.5M — ARCH Venture Partners, HealthCare Ventures, Canaan Partners, Alexandria Venture Investments, Amgen Ventures, MPM BioImpact
- Series B, Mar 19, 2007, $29M — ARCH Venture Partners, HealthCare Ventures, Canaan Partners, Alexandria Venture Investments, Amgen Ventures, MPM BioImpact, Accelerator Life Science Partners
- Series A, Feb 6, 2006, $1.5M — ARCH Venture Partners
- Series A, Oct 1, 2004, $2M — ARCH Venture Partners, OVP Venture Partners, Versant Ventures, Alexandria Venture Investments, Amgen Ventures, MPM BioImpact, Accelerator Life Science Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- OVP Venture Partners (https://capitalatlas.ai/funds/ovp-venture-partners) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series A, Series B
- HealthCare Ventures — Series B, Series C
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B, Series C
- Zenyaku Kogyo Co., Ltd. — Series B